<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28441">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01933516</url>
  </required_header>
  <id_info>
    <org_study_id>GP13-101</org_study_id>
    <nct_id>NCT01933516</nct_id>
  </id_info>
  <brief_title>GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Phase I Trial to Assess the Safety and Pharmacokinetics of GP2013 Monotherapy Administered Weekly in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz K.K.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sandoz K.K.</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and pharmacokinetic of GP2013 in Japanese
      patients with CD20 positive low tumor burden indolent B-cell NHL under weekly dosing
      schedule.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To evaluate safety of GP2013</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Adverse events, laboratory abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve calculated from start of dose to the end of the dosing interval (tau) of GP2013</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration of GP2013</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum concentration of GP2013</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum (trough) observed concentration during each dosing interval of GP2013</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination rate constant calculated as the slope of the linear regression of the terminal phase of the logarithmic concentration-time profile of GP2013</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination half-life associated with the terminal slope of GP2013</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate efficacy of GP2013</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Antitumor activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the incidence of immunogenicity (ADA formation) against GP2013</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Immunogenicity (ADA formation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate peripheral CD19+ B-cell count</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>CD19 + B-cell count</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Indolent B-cell Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>GP2013</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GP2013</intervention_name>
    <description>GP2013</description>
    <arm_group_label>GP2013</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with CD20 positive low tumor burden indolent B-cell non- Hodgkin's lymphoma.

          -  Patient with at least one measurable lesion.

          -  Patient with ECOG performance status 0 or 1.

        Exclusion Criteria:

          -  Patient who has received radiotherapy within the last 28 days prior to
             administration, or are not recovered from previous radiotherapy.

          -  Patient who has received immunotherapy, chemotherapy, antibodies and experimental
             treatment within the last 28 days prior to administration, or are not recovered from
             previous therapy.

          -  Patient who has mAb therapy other than rituximab as prior line of therapy.

          -  Patient with evidence of any uncontrolled, acute or chronic active infection (viral,
             bacterial or fungal).

          -  Patient with any other malignancy within 5 years prior to date of screening, with the
             exception of adequately treated in situ carcinoma of the cervix uteri, basal or
             squamous cell carcinoma or nonmelanomatous skin cancer.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandoz K.K.</last_name>
    <role>Study Director</role>
    <affiliation>Sandoz K.K.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandoz K.K.</last_name>
    <phone>+81-3-5469-3101</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Tachikawa</city>
        <state>Tokyo</state>
        <zip>190-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 28, 2013</lastchanged_date>
  <firstreceived_date>August 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GP2013</keyword>
  <keyword>Japanese</keyword>
  <keyword>indolent B-cell non-Hodgkin's lymphoma</keyword>
  <keyword>biosimilar</keyword>
  <keyword>CD20</keyword>
  <keyword>GP13-101</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
